JPMorgan Chase & Co. Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $64.00
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price cut by JPMorgan Chase & Co. from $72.00 to $64.00 in a research report released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. A number of other equities research analysts have also weighed in on APLS. HC Wainwright cut […]
More Stories
Southern Silver Exploration (CVE:SSV) Trading 5.4% Higher – Here’s Why
Southern Silver Exploration Corp. (CVE:SSV – Get Free Report)’s share price was up 5.4% on Wednesday . The company traded...
iShares Currency Hedged MSCI Italy ETF (NYSEARCA:HEWI) Stock Price Down 0.5% – What’s Next?
iShares Currency Hedged MSCI Italy ETF (NYSEARCA:HEWI – Get Free Report) traded down 0.5% during mid-day trading on Wednesday ....
Renishaw plc (OTCMKTS:RNSHF) Short Interest Update
Renishaw plc (OTCMKTS:RNSHF – Get Free Report) was the recipient of a significant drop in short interest in December. As...
iShares Transition-Enabling Metals ETF (NASDAQ:TMET) Sees Large Increase in Short Interest
iShares Transition-Enabling Metals ETF (NASDAQ:TMET – Get Free Report) was the recipient of a significant increase in short interest during...
British Smaller Companies VCT2 (LON:BSC) Shares Down 1.9% – Time to Sell?
British Smaller Companies VCT2 (LON:BSC – Get Free Report)’s share price was down 1.9% on Wednesday . The stock traded...
DiamondPeak (OTCMKTS:DPHCU) Shares Down 13.7% – Should You Sell?
DiamondPeak Holdings Corp. (OTCMKTS:DPHCU – Get Free Report)’s share price fell 13.7% during trading on Wednesday . The company traded...